德国Trigen开发出新型静脉内抗凝剂TGN255

 
一项II期临床研究的结果提示，一种新型候选药物是有效而便利的抗凝剂。在2005年8月澳大利亚悉尼举行的国际血栓与止血学会第20届大会上报道了这些研究结果。

这种新型化合物叫做TGN255，是由德国Trigen控股公司研制开发的。该公司在欧洲一些医疗机构的28例接受血液透析的患者中进行了该项研究，评估了TGN255是否能够防止终末期肾脏功能衰竭的血液透析患者体外循环的凝血，以及药物的药效动力学和药物代谢动力学。研究结果显示TGN255确实能够提供有效而便利的抗凝作用，控制水平极高而且并不增加出血危险。

TGN255是一种新型静脉内小分子直接凝血酶抑制剂(DTI)，被开发用于医院内可预测和安全抗凝候选药物。这项研究的最终结果将在2005年秋天获得。但是Trigen相信，初步研究结果支持TGN255进入后期临床试验。Trigen是一家生物技术公司，侧重于血栓与血管功能失调。该公司已经开发了两个平台，SIGSCREEN和THROMSCAN，已经成功用于几家跨国制药公司的合作。

New Intravenous Anticoagulant
 
The results of a phase II study suggest that a new drug candidate is an effective and convenient anticoagulant. The results were reported at the 20th Congress of the International Society of Thrombosis and Haemostasis (ISTH) held in Sydney (Australia) in August 2005.

The new compound, known as TGN 255, was developed by Trigen Holdings AG (Munich, Germany). The company conducted the study in 28 patients undergoing hemodialysis at several sites in Europe to assess whether TGN 255 would adequately anticoagulate the extracorporeal circuit in hemodialysis in patients with end-stage renal failure and to evaluate the pharmacokinetics and pharmacodynamics of the drug in that setting. The results showed that TGN 255 did provide effective and convenient anticoagulant cover in this setting with a high level of control and with no increase in bleeding risk.

TGN 255 is a novel, intravenous small-molecule direct thrombin inhibitor (DTI) being developed as a predictable and safer alternative for anticoagulation in hospital settings. The final results of the study will be available in the fall of 2005. However, Trigen believes the preliminary data support the progression of TGN 255 into late-stage clinical trials. Trigen is a biotechnology company, focusing on thrombosis and vascular dysfunction. The company has developed two discovery platforms, SIGSCREEN and THROMSCAN, which have been applied in collaborations with a number of multinational pharmaceutical firms.